Leukemia Clinical Trials in Boston, Massachusetts

16 studies are recruiting for leukemia in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing

   This study aims to test the Tools for Reducing Inequity in Acute Leukemia (TRIAL) web-based application that is designed to support participants with acute leukemia by providing information and resources about leukemia and clinical trial participation.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT06907797 on ClinicalTrials.gov

2. Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

   This is an open label, non-randomized, multicenter, pilot, dose expansion study of low dose post-transplant cyclophosphamide (25 mg/kg on Days +3 and +4)/tacrolimus/ruxolitinib in the setting of myeloablative conditioning (MAC) allogeneic peripheral blood stem cell transplantation (PBSCT).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   3 in total

   Run by

   Hannah Choe, MD

   See if you can join NCT07249346 on ClinicalTrials.gov

3. CIML NK Cells With Venetoclax for AML

   The purpose of this research study is to test the safety and to explore the effectiveness of infusing cytokine- induced memory-like (CIML) natural killer (NK) cells in combination with Interleukin-2 (IL-2) and standard-of-care venetoclax as a treatment for Acute Myeloid Leukemia (AML) with measurab…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Brigham and Women's Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT06152809 on ClinicalTrials.gov

4. Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia

   This study is to evaluate the safety and preliminary efficacy of adding the PI3K-gamma inhibitor, eganelisib, to a standard of care treatment option with combination venetoclax and azacitidine in participants with acute myeloid leukemia (AML). The names of the study drugs involved in this research …

   Stage

   Phase 1

   Ages

   18 to 90

   Site

   Brigham and Women's Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Jacqueline Garcia, MD

   See if you can join NCT07439211 on ClinicalTrials.gov

5. Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

   The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Beth Israel Deaconess Medical Center, Boston, Massachusetts

   Locations

   45 in total

   Run by

   Kura Oncology, Inc.

   See if you can join NCT06001788 on ClinicalTrials.gov

6. ALL Backbone in AYAs

   The goal of this research study is to evaluate a chemotherapy regiment for the treatment of newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs). The names of the study drugs involved in this study are: * blinatumomab (a type of …

   Stage

   Phase 2

   Ages

   18 to 51

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT07227584 on ClinicalTrials.gov

7. Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens

   This research study is a genomic profiling and repository study for children and young adults who have leukemia, myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS). Genes are the part of cells that contain the instructions which tell cells how to make the right proteins to grow and…

   Stage

   Not phased

   Ages

   Up to 30

   Site

   Boston Children's Hospital, Boston, Massachusetts

   Locations

   8 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT04968834 on ClinicalTrials.gov

8. Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)

   The purpose of this research study is to enhance inclusion and diversity in clinical trial enrollment by training participants to perform and provide feedback through a community-based protocol review process, called DIVERSE.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT06469307 on ClinicalTrials.gov

9. Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

   The purpose of this research study is to test the safety and efficacy of cytokine induced memory-like (CIML) natural killer (NK) cells expanded with Interleukin-2 (IL-2) at preventing relapse in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or MDS and myeloproliferative neoplasm (MP…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT06138587 on ClinicalTrials.gov

10. Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy

    The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular therapy (ACT). After completion of an open pilot, participants will be rando…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Massachusetts General Hospital Cancer Center, Boston, Massachusetts

    Run by

    Massachusetts General Hospital

    See if you can join NCT05646576 on ClinicalTrials.gov

11. Revumenib in Combination With 7+3 + Midostaurin in AML

    This research is being conducted to determine a safe and effective dose of revumenib that can be given in combination with standard induction (initial therapy to induce a remission) + FLT3 targeted therapy (midostaurin) and a single cycle of post-remission therapy + FLT3 targeted therapy (midostaur…

    Stage

    Phase 1

    Ages

    18 to 75

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Richard Stone, MD

    See if you can join NCT06313437 on ClinicalTrials.gov

12. Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

    This research study will test the safety and anticancer activity of the combination of three drugs (Roginolisib, Venetoclax, and Rituximab) for participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL). The names of the study drugs involved in this study are: * Roginolisib (a nove…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Run by

    Jennifer R. Brown, MD, PhD

    See if you can join NCT06644183 on ClinicalTrials.gov

13. A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

    The purpose of this research study is to test the safety and efficacy of a new drug combination with three agents, azacitidine, venetoclax and tagraxofusp. Leftover (residual) leukemia disease that is not visible by eye can be increase the chance of disease recurrence. This research study is to det…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Jacqueline Garcia, MD

    See if you can join NCT07148180 on ClinicalTrials.gov

14. Mosunetuzumab for CLL MRD Clearance

    The goal of this study is to test mosunetuzumab given alone or in combination with a Bruton tyrosine kinase inhibitor (BTKi, such as ibrutinib, acalabrutinib, zanubrutinib, or pirtobrutinib) in participants with CLL (chronic lymphocytic leukemia) or small lymphocytic lymphoma (SLL). The names of th…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Brigham & Women's Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Inhye Ahn

    See if you can join NCT07052695 on ClinicalTrials.gov

15. I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients

    The goal of this study is to see if patients with myeloproliferative disorders are able to successfully complete the Cardiac Lifestyle Program(CLP). The goal of the CLP is to teach patients how to become more active and eat healthier foods. The name of the intervention used in this research study i…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Locations

    3 in total

    Run by

    Massachusetts General Hospital

    See if you can join NCT05842603 on ClinicalTrials.gov

16. HEME Home Transfusion Program

    This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared to regular standard of care improves quality of life, mood, and end-of-life health care utilization for patients with hematologic malignancie…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT06487247 on ClinicalTrials.gov